share_log

Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $125

Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $125

巴克萊維持對Zimmer Biomet Holdings的減持,將目標股價下調至125美元
Benzinga ·  05/31 14:16

Barclays analyst Matt Miksic maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Underweight and lowers the price target from $130 to $125.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論